Biogen Q2 2026: Revenue Beats but EPS Plunges 85% on Apellis Integration Costs and Pipeline Milestones
BIIB sits 64% above its 52-week low of $124.556.
Summary
Biogen reported Q2 2026 revenue of $2.74B, beating estimates, but net income fell 85% to $97.5M due to Apellis integration costs, pipeline investments, and restructuring charges. The company also announced the RayThera acquisition and the discontinuation of BIIB122.
Key Events · Earnings and Guidance · BIIB
-
Q2 Revenue Beats, Earnings Miss
Total revenue of $2.74B (+3.4% YoY) exceeded consensus, but net income attributable to Biogen fell to $97.5M from $634.8M, with diluted EPS of $0.66 vs. $4.33 a year ago.
-
Apellis Integration Drives Restructuring
Recognized $165.4M in restructuring charges, primarily severance and accelerated bonus payments, as part of the Apellis integration plan to realize operating synergies.
-
Pipeline Milestones and IPR&D Expense
Acquired IPR&D, upfront and milestone expense totaled $164.0M, including a $100M payment to TJ Bio for felzartamab rights in greater China and a $45M milestone to Ionis for salanersen Phase 3 initiation.
-
RayThera Acquisition Announced
Entered into a definitive agreement to acquire RayThera Inc. for $225M upfront plus up to $775M in milestones, adding a Phase 1 immunology asset.
Analysis · BIIB · Life Sciences
A top-line beat to $2.74B in Q2 revenue was overshadowed by a dramatic earnings collapse, as net income fell from $634.8M a year ago to just $97.5M. The decline was driven by $165M in restructuring charges tied to the Apellis integration, $164M in acquired IPR&D and milestone expenses—including $100M for felzartamab rights—and higher amortization from inventory step-ups. Beyond the numbers, the company disclosed a definitive agreement to acquire RayThera for $225M upfront, discontinued the BIIB122 Parkinson's program with Denali, and reported multiple litigation and regulatory developments. The results highlight a transformative period in which Biogen is absorbing a major acquisition while advancing its pipeline, but at a steep near-term cost to earnings.
At the time of this filing, BIIB was trading at $204.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.4B. The 52-week trading range was $124.56 to $219.72. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.